Switzerland's healthcare system is often regarded as a benchmark for high-quality healthcare, as evidenced by the country's high life expectancy and the level of health spending. Healthcare expenditure as a percentage of GDP (Gross Domestic Product) tends to be higher in countries with higher life expectancies.
Switzerland's healthcare expenditure is comparatively high, ranking fifth globally in health spending as a percentage of GDP. In 2020, the average expenditure on healthcare in OECD countries rose to 9.7% of GDP, an increase from 8.8% in 2019. Switzerland ranks behind only the USA, Germany, France, and the UK with a percentage of 11.8%.
In addition, Switzerland leads in the number of biotechnology patent applications filed to the PCT[1] per capita per year, with companies filing 253 biotechnology patent applications in 2019. This is a remarkable achievement considering the country's small population, with almost 30 patent applications per million inhabitants. Denmark is in second place with 28 patent applications per million inhabitants, followed by Israel in third place with 25. Patents are critical to the pharmaceutical industry to ensure that money can continue to be reinvested in research and development.
Switzerland's healthcare system and the country's high healthcare spending are a testament to the government's commitment to providing excellent healthcare to its citizens. Additionally, Switzerland's leadership in patent applications demonstrates the country's ongoing innovation and research initiatives. This data highlights the importance of investing in healthcare infrastructure and innovation in driving progress and improving healthcare outcomes.
Are you looking for a partner to help you navigate the complex Swiss pharmaceutical market and unlock its potential? Look no further than Swizzard. As a Swiss company, we have the expertise and experience to guide you through every step of the process, from building the company to setting up the strategy to implementing the launch. Our goal is to help you achieve success in the highly attractive Swiss pharmaceutical market, and we're committed to being your trusted partner every step of the way. Contact us today to learn more about our services and how we can work together to achieve your goals.
If you should have any questions about the Swiss healthcare market, feel free to contact our CEO Michael Zürcher at michael@swizzard-pharma.com or fill out our contact form - we're happy to help!
[1] PCT: Patent Cooperation Treaty (Patent Cooperation Treaty). The treaty makes it possible to apply for patent protection for an invention in a large number of countries simultaneously by filing an "international" patent application. It was signed by the member states of the Paris Convention for the Protection of Industrial Property (1883). back to text ->
Sources
Interpharma Health Panorama 2022
Swiss Federal Statistical Office BfS 2023
